+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

IVD Raw Materials Market - Global Outlook & Forecast 2022-2027

  • PDF Icon

    Report

  • 342 Pages
  • June 2022
  • Region: Global
  • Arizton
  • ID: 5614355
UP TO OFF until Sep 30th 2022
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

With the rise in chronic conditions and patient populations, the demand for diagnostics and laboratory tests increases. The growing demand for antigen and antibody-based tests that increased during COVID-19 led to its major market share.

The Europe region is one of the matured markets for in-vitro diagnostic; the large laboratory instruments are highly automated compared to most point-of-care testing devices. Automation has increased the speed and ease of using the devices the workforce is thoroughly trained and adopted. Furthermore, the global IVD raw materials market is expected to witness an incremental growth of USD 9.91 billion and absolute growth of 40.73% by 2027.

The following factors are likely to contribute to the growth of the IVD raw materials market during the forecast period:

  • Increasing Prevalence of Infectious & Chronic Diseases
  • Growing Awareness for Early Diagnosis and Disease Prevention
  • Surge In Demand for IVD Testing & Devices
  • Rise In Availability of Advanced Home Care Kits for Cancer Diagnostics

KEY HIGHLIGHTS

  • Growing trends for point of care diagnostics and personalized medicine contribute to the growth of the IVD raw materials market.
  • Investment in the development and commercial launch of IVD instruments and rapid test kits to diagnose several infectious diseases and their applications in the research segment will boost the market in developed countries.
  • In 2021, pharma & biotech companies accounted for the major share of 62.19% in the global IVD raw materials market. However, diagnostic laboratories are likely to witness the highest absolute growth of 43.37% during the forecast period.
  • Vendors offer a broad portfolio of quality enzymes that are highly suitable for manufacturing diagnostic kits and reagents. Manufacturers are also exploring new enzyme sources from enormous enzymes and optimizing and transforming the most appropriate enzyme molecules.

THIS RESEARCH REPORT INCLUDE A DETAILED SEGMENTATION ANALYSIS BY:

  • Product
  • Technology
  • End-User
  • Geography

SEGMENTATION ANALYSIS


Rapid tests developed through clinical chemistry provides test results immediately. Manufacturers offer many IVD raw materials applicable to clinical chemistry methods. The global IVD raw materials market by clinical chemistry is expected to reach USD 12.14 billion by 2027. Furthermore, private laboratories have expanded their footprints in recent years, especially in developing countries, which has stimulated market growth. Moreover, the demand for standalone reference laboratories is gradually rising due to the prevalence of epidemic and pandemic conditions across the globe. The global IVD raw materials market by diagnostic laboratories will grow at a CAGR of over 6% during 2022-2027.
  • Segmentation Analysis by Product
  • Antibody & Antigen
  • Enzymes
  • Proteins
  • Biological Buffers
  • Others
  • Segmentation Analysis by Technology
  • Clinical Chemistry
  • Immunochemistry
  • Molecular Diagnostics
  • Others
  • Segmentation Analysis by End-User
  • Pharma & Biotech Companies
  • Diagnostic Laboratories
  • Others

COMPETITIVE LANDSCAPE


Major manufacturers of IVD raw materials are focusing on their proprietary processing techniques that satisfy the raw material requirements of the IVD industry and provide IVD raw materials made to their own with the off-the-shelf specification. Vendors are constantly investing resources in R&D projects based on market trends and the demand for general health management. Key players are also engaged in strategic acquisitions as part of their inorganic growth strategy to enhance sales and profit margins. Strategic M&As continue to be an essential competitive strategy for key players to expand product offerings, access new technology, or increase market share. Vendors also focus on developing and commercializing innovative analyzers, COVID-19 PCR rapid test kits, and consumables to remain competitive and gain a significant presence in the IVD raw materials market.

Key Vendors

  • Aalto Bio Reagents
  • Fapon Biotech
  • Fujirebio
  • Merck KGaA
  • Hoffmann-La Roche
  • Thermo Fisher Scientific

Other Prominent Vendors

  • ABclonal
  • BBI Solutions
  • Beijing Diagreat Biotechnology
  • Biofootprints Healthcare
  • BioPorto
  • Creative Diagnostics
  • CUSABIO Technology
  • EUPROTEIN
  • Eximio Biotec
  • GenScript ProBio
  • Getein Biotech
  • Glentham Life Sciences
  • HyTest
  • ImmunoDiagnostics
  • LGC
  • Medix Biochemica
  • Meridian Bioscience
  • More Diagnostics
  • MP Biomedicals
  • Nanjing Okay Biotechnology
  • Nitto Boseki
  • OYC Europe
  • Prahas Healthcare
  • Promega
  • ReAgent
  • Rockland Immunochemicals
  • Sekisui Diagnostics
  • SERION Immunologics
  • Signalway Antibody
  • Suzhou Yacoo Science
  • Trina Bioreactives
  • Watson International
  • Wuhan Huamei Biotech

GEOGRAPHICAL ANALYSIS


In 2021, Europe dominated the global IVD raw materials market compared to other regions. This region is a mature market with developed diagnostic infrastructure available in most countries. The demand for advanced molecular diagnostics in the European countries has gone high owing to the presence of advanced infrastructure in healthcare diagnosis. Point of care diagnostics is the latest trend in the European market. The Europe IVD raw materials market is expected to reach USD 11.80 billion by 2027.
  • Geography
  • Europe
  • Germany
  • Italy
  • France
  • UK
  • Spain
  • North America
  • US
  • Canada
  • APAC
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Middle East & Africa
  • Turkey
  • Saudi Arabia
  • South Africa

Table of Contents

1 Research Methodology2 Research Objectives3 Research Process
4 Scope & Coverage
4.1 Market Definition
4.2 Base Year
4.3 Scope of the Study
5 Report Assumptions & Caveats
5.1 Key Caveats
5.2 Currency Conversion
5.3 Market Derivation
6 Market at a Glance
7 Introduction
7.1 Overview
8 Market Opportunities & Trends
8.1 Growing Demand for Point-Of-Care Pcr Diagnostics
8.2 Surge in Preference for Personalized Medicine
8.3 Rise in Demand for Molecular Diagnostics
8.4 Advanced Technologies in Ivd Products
9 Market Growth Enablers
9.1 Increasing Prevalence of Infectious & Chronic Diseases
9.2 Growing Awareness of Early Diagnosis and Disease Prevention
9.3 High Demand for Ivd Tests & Devices
9.4 Rise in Availability of Advanced Home Care Kits for Cancer Diagnostics
10 Market Restraints
10.1 Lot-To-Lot Variations in Ivd Reagents
10.2 Stringent Regulations for Product Approvals
10.3 Lower Penetration of Ivd Devices in Lmics
11 Market Landscape
11.1 Market Overview
11.2 Market Size & Forecast
11.3 Five Forces Analysis
12 Product
12.1 Market Snapshot & Growth Engine
12.2 Market Overview
12.3 Antibodies & Antigens
12.4 Enzymes
12.5 Proteins
12.6 Biological Buffers
12.7 Others
13 Technology
13.1 Market Snapshot & Growth Engine
13.2 Market Overview
13.3 Clinical Chemistry
13.4 Immunochemistry
13.5 Molecular Diagnostics
13.6 Others
14 End-user
14.1 Market Snapshot & Growth Engine
14.2 Market Overview
14.3 Pharma/Biotech & Medtech Companies
14.4 Diagnostic Laboratories
14.5 Others
15 Geography
15.1 Market Snapshot & Growth Engine
15.2 Geographic Overview
16 Europe
16.1 Market Overview
16.2 Market Size & Forecast
16.3 Key Countries
17 North America
17.1 Market Overview
17.2 Market Size & Forecast
17.3 Key Countries
18 Apac
18.1 Market Overview
18.2 Market Size & Forecast
18.3 Key Countries
19 Latin America
19.1 Market Overview
19.2 Market Size & Forecast
19.3 Key Countries
20. Middle East & Africa
20.1 Market Overview
20.2 Market Size & Forecast
20.3 Key Countries
21. Competitive Landscape
21.1 Competition Overview
21.2 Market Share Analysis
22. Key Company Profiles
22.1 Aalto Bio Reagents
22.2 Fapon Biotech
22.3 Fujirebio
22.4 Merck Kgaa
22.5 F. Hoffmann-La Roche
22.6 Thermo Fisher Scientific
23. Other Prominent Vendors
23.1 Abclonal
23.2 Bbi Solutions
23.3 Beijing Diagreat Biotechnology
23.4 Biofootprints Healthcare
23.5 Bioporto
23.6 Creative Diagnostics
23.7 Cusabio Technology
23.8 Euprotein
23.9 Eximio Biotec
23.10 Genscript Probio
23.11 Getein Biotech
23.12 Glentham Life Sciences
23.13 Hytest
23.14 Immunodiagnostics
23.15 Lgc
23.16 Medix Biochemica
23.17 Meridian Bioscience
23.18 More Diagnostics
23.19 Mp Biomedicals
23.20 Nanjing Okay Biotechnology
23.21 Nitto Boseki
23.22 Oyc Europe
23.23 Prahas Healthcare
23.24 Promega
23.25 Reagent
23.26 Rockland Immunochemicals
23.27 Sekisui Diagnostics
23.28 Serion Immunologics
23.29 Signalway Antibody
23.30 Suzhou Yacoo Science
23.31 Trina Bioreactives
23.32 Watson International
23.33 Wuhan Huamei Biotech
24. Report Summary
24.1 Key Takeaways
24.2 Strategic Recommendations
25. Quantitative Summary
25.1 Market by Product
25.2 Market by Technology
25.3 Market by End-user
25.4 Market by Geography
26. Appendix
26.1 Abbreviations

Companies Mentioned

  • Aalto Bio Reagents
  • Fapon Biotech
  • Fujirebio
  • Merck KGaA
  • Hoffmann-La Roche
  • Thermo Fisher Scientific
  • ABclonal
  • BBI Solutions
  • Beijing Diagreat Biotechnology
  • Biofootprints Healthcare
  • BioPorto
  • Creative Diagnostics
  • CUSABIO Technology
  • EUPROTEIN
  • Eximio Biotec
  • GenScript ProBio
  • Getein Biotech
  • Glentham Life Sciences
  • HyTest
  • ImmunoDiagnostics
  • LGC
  • Medix Biochemica
  • Meridian Bioscience
  • More Diagnostics
  • MP Biomedicals
  • Nanjing Okay Biotechnology
  • Nitto Boseki
  • OYC Europe
  • Prahas Healthcare
  • Promega
  • ReAgent
  • Rockland Immunochemicals
  • Sekisui Diagnostics
  • SERION Immunologics
  • Signalway Antibody
  • Suzhou Yacoo Science
  • Trina Bioreactives
  • Watson International
  • Wuhan Huamei Biotech

Methodology


Our research comprises a mix of primary and secondary research. The secondary research sources that are typically referred to include, but are not limited to, company websites, annual reports, financial reports, company pipeline charts, broker reports, investor presentations and SEC filings, journals and conferences, internal proprietary databases, news articles, press releases, and webcasts specific to the companies operating in any given market.

Primary research involves email interactions with the industry participants across major geographies. The participants who typically take part in such a process include, but are not limited to, CEOs, VPs, business development managers, market intelligence managers, and national sales managers. We primarily rely on internal research work and internal databases that we have populated over the years. We cross-verify our secondary research findings with the primary respondents participating in the study.



 

Loading
LOADING...